Tags

Type your tag names separated by a space and hit enter

[Measurement of the serum concentrations of tumor necrosis factor alpha and its soluble receptors in normal and pre-eclamptic pregnant patients].
Invest Clin. 2001 Sep; 42(3):171-81.IC

Abstract

A multicenter prospective clinical study was designed with the purpose of measure tumor necrosis factor alpha (TNF alpha) and tumor necrosis factor alpha-receptors p55 and p75 (sTNF alpha-p55 and sTNF alpha-p75) in normal pregnancy and preeclampsia (PE). Blood samples were collected without anticoagulant from 30 pregnant women, matched for chronological and gestational age, 15 healthy pregnant (group A) and 15 women with PE (group B). TNF alpha was measured by enzyme linked immunosorbent assay and sTNF alpha-p55 and sTNF alpha-p75 were measured by amplified immunoenzymometric assay. The statistical analysis was carried out using the paired t Student test. The values of TNF alpha were 7.07 +/- 1.63 pg/mL (mean +/- SE) in group A and 16.43 +/- 2.92 in group B pg/mL (p < 0.05).); concentrations of sTNF alpha-p55 were 2.69 +/- 0.17 ng/mL and 5.18 +/- 0.54 ng/mL in groups A and B respectively (p < 0.001); sTNF alpha-p75 reached levels of 5.94 +/- 0.27 ng/mL in healthy pregnant and 9.02 +/- 0.66 ng/mL in patients with PE (p < 0.001). TNF alpha, sTNF alpha-p55 and sTNF alpha-p75 were significantly higher in preeclamptic women than in normotensive controls. These findings indicate that the levels of TNF alpha, el TNF alpha-p55 and TNF alpha-p75 were elevated in PE. Further research is needed to identify modifiable risk factors for the excessive synthesis and release of TNF alpha in pregnancy, and to assess whether the lowering of TNF alpha concentrations in pregnancy alters the incidence and severity of PE.

Authors+Show Affiliations

Núñez-González JR
Cátedra de Inmunología, Escuela de Medicina, Facultad de Medicina de La Universidad del Zulia, Maracaibo-Venezuela.
Sanabria-Vera CJ
No affiliation info available
Romero-Adrián T
No affiliation info available

MeSH

AdultAntigens, CDBlood PressureFemaleGestational AgeHumansImmunoenzyme TechniquesPre-EclampsiaPregnancyProspective StudiesProteinuriaReceptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IIRisk FactorsSolubilityTumor Necrosis Factor-alphaVenezuela

Pub Type(s)

English Abstract
Journal Article
Multicenter Study

Language

spa

PubMed ID

11552506

Citation

Núñez-González, J R., et al. "[Measurement of the Serum Concentrations of Tumor Necrosis Factor Alpha and Its Soluble Receptors in Normal and Pre-eclamptic Pregnant Patients]." Investigacion Clinica, vol. 42, no. 3, 2001, pp. 171-81.
Núñez-González JR, Sanabria-Vera CJ, Romero-Adrián T. [Measurement of the serum concentrations of tumor necrosis factor alpha and its soluble receptors in normal and pre-eclamptic pregnant patients]. Invest Clin. 2001;42(3):171-81.
Núñez-González, J. R., Sanabria-Vera, C. J., & Romero-Adrián, T. (2001). [Measurement of the serum concentrations of tumor necrosis factor alpha and its soluble receptors in normal and pre-eclamptic pregnant patients]. Investigacion Clinica, 42(3), 171-81.
Núñez-González JR, Sanabria-Vera CJ, Romero-Adrián T. [Measurement of the Serum Concentrations of Tumor Necrosis Factor Alpha and Its Soluble Receptors in Normal and Pre-eclamptic Pregnant Patients]. Invest Clin. 2001;42(3):171-81. PubMed PMID: 11552506.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Measurement of the serum concentrations of tumor necrosis factor alpha and its soluble receptors in normal and pre-eclamptic pregnant patients]. AU - Núñez-González,J R, AU - Sanabria-Vera,C J, AU - Romero-Adrián,T, PY - 2001/9/13/pubmed PY - 2001/10/26/medline PY - 2001/9/13/entrez SP - 171 EP - 81 JF - Investigacion clinica JO - Invest Clin VL - 42 IS - 3 N2 - A multicenter prospective clinical study was designed with the purpose of measure tumor necrosis factor alpha (TNF alpha) and tumor necrosis factor alpha-receptors p55 and p75 (sTNF alpha-p55 and sTNF alpha-p75) in normal pregnancy and preeclampsia (PE). Blood samples were collected without anticoagulant from 30 pregnant women, matched for chronological and gestational age, 15 healthy pregnant (group A) and 15 women with PE (group B). TNF alpha was measured by enzyme linked immunosorbent assay and sTNF alpha-p55 and sTNF alpha-p75 were measured by amplified immunoenzymometric assay. The statistical analysis was carried out using the paired t Student test. The values of TNF alpha were 7.07 +/- 1.63 pg/mL (mean +/- SE) in group A and 16.43 +/- 2.92 in group B pg/mL (p < 0.05).); concentrations of sTNF alpha-p55 were 2.69 +/- 0.17 ng/mL and 5.18 +/- 0.54 ng/mL in groups A and B respectively (p < 0.001); sTNF alpha-p75 reached levels of 5.94 +/- 0.27 ng/mL in healthy pregnant and 9.02 +/- 0.66 ng/mL in patients with PE (p < 0.001). TNF alpha, sTNF alpha-p55 and sTNF alpha-p75 were significantly higher in preeclamptic women than in normotensive controls. These findings indicate that the levels of TNF alpha, el TNF alpha-p55 and TNF alpha-p75 were elevated in PE. Further research is needed to identify modifiable risk factors for the excessive synthesis and release of TNF alpha in pregnancy, and to assess whether the lowering of TNF alpha concentrations in pregnancy alters the incidence and severity of PE. SN - 0535-5133 UR - https://www.unboundmedicine.com/medline/citation/11552506/[Measurement_of_the_serum_concentrations_of_tumor_necrosis_factor_alpha_and_its_soluble_receptors_in_normal_and_pre_eclamptic_pregnant_patients]_ L2 - https://antibodies.cancer.gov/detail/CPTC-SIGLEC7-1 DB - PRIME DP - Unbound Medicine ER -